Wall Street brokerages expect Kadmon Holdings, Inc. (NYSE:KDMN) to report earnings per share (EPS) of ($0.34) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Kadmon’s earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.26). Kadmon posted earnings of ($0.50) per share in the same quarter last year, which suggests a positive year over year growth rate of 32%. The business is scheduled to issue its next quarterly earnings report on Wednesday, March 28th.
On average, analysts expect that Kadmon will report full-year earnings of ($1.61) per share for the current fiscal year, with EPS estimates ranging from ($1.71) to ($1.51). For the next financial year, analysts forecast that the firm will post earnings of ($1.43) per share, with EPS estimates ranging from ($1.89) to ($1.08). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Kadmon.
Kadmon (NYSE:KDMN) last issued its earnings results on Thursday, November 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.04). The firm had revenue of $2.28 million for the quarter, compared to analysts’ expectations of $5.69 million. During the same quarter last year, the company earned ($4.24) EPS. The business’s revenue was down 60.0% on a year-over-year basis.
Shares of Kadmon (KDMN) traded down $0.09 during trading on Friday, hitting $3.55. 1,110,200 shares of the stock traded hands, compared to its average volume of 289,980. Kadmon has a 1 year low of $2.05 and a 1 year high of $5.93.
A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in Kadmon by 166.0% during the second quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock valued at $5,870,000 after buying an additional 941,549 shares during the period. Sphera Funds Management LTD. purchased a new position in Kadmon during the third quarter valued at $3,685,000. Crestline Management LP purchased a new position in Kadmon during the third quarter valued at $2,011,000. Sabby Management LLC purchased a new position in Kadmon during the second quarter valued at $2,112,000. Finally, Susquehanna International Group LLP lifted its position in Kadmon by 3,211.2% during the third quarter. Susquehanna International Group LLP now owns 443,135 shares of the company’s stock valued at $1,485,000 after buying an additional 429,752 shares during the period. 51.90% of the stock is owned by institutional investors and hedge funds.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.